Skip navigation
July 14, 2022

Natera Selected for UnitedHealthcare’s Preferred Laboratory Network

AUSTIN, Texas, July 14, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced it has been selected to participate in UnitedHealthcare’s Preferred Laboratory Network (PLN). Natera’s addition to the network was effective July 1, 2022.

UnitedHealthcare’s PLN consists of laboratory care providers that have met the insurer’s highest standards for access, cost, data, quality and service, based on a rigorous application and review process. UnitedHealthcare works with these labs to continue its efforts to improve the care providers and members’ experience.

UnitedHealthcare describes the PLN as "an advanced way to work with selected lab providers to deliver care that places a greater emphasis on patient outcomes and the total cost of a person’s care."

"Natera is pleased to be part of UnitedHealthcare’s PLN and we look forward to continuing to provide UHC plan members with an outstanding experience," said Matthew Mega, vice president, market access at Natera. "We remain committed to making personalized genetic testing and diagnostics part of the standard of care."

Since its inception, Natera has performed more than 3 million cfDNA tests worldwide, helping patients and their providers make critical health care decisions in oncology, women’s health and organ health.

UnitedHealthcare offers the full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1.5 million physicians and care professionals, and 7,000 hospitals and other care facilities nationwide.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, and our ability to grow our business. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., 720-318-4080 pr@natera.com

SOURCE Natera, Inc.